Effect of selenium in treatment of gestational diabetes

Effect of selenium supplementation on insulin resistance, oxidative stress and inflammatory factors in women with gestational diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201403175623N18

Enrollment

Registered

2014-03-25

Start date

2014-03-18

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes mellitus. Diabetes mellitus in pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Selenium capsule, 200 µg, daily for 6 weeks orally. Intervention 2: Control group: Placebo capsule, daily for 6 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Pregnant women aged 18-40 years Pregnant women diagnosed with gestational diabetes mellitus 24-28 weeks' gestation

Exclusion criteria

Exclusion criteria: Intrauterine fetal death Premature preterm rupture of membrane Placenta abruption Preeclampsia Eclampsia Chronic hypertension Hypo- or hyperthyroidism Urinary tract infection Smokers Kidney or liver diseases Those taking estrogen therapy Stressful life conditions

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.	—

Secondary

Measure	Time frame
Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Systolic blood pressures. Timepoint: Baseline and End-of-trial. Method of measurement: Sphygmomanometer.;Diastolic blood pressure. Timepoint: Baseline and End-of-trial. Method of measurement: Sphygmomanometer.	—

Measure

Time frame

Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Systolic blood pressures. Timepoint: Baseline and End-of-trial. Method of measurement: Sphygmomanometer.;Diastolic blood pressure. Timepoint: Baseline and End-of-trial. Method of measurement: Sphygmomanometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026